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Introduction
Cancer is the leading cause of death in high-income 
Abstract
Introduction: The present study aimed to determine the alterations in the serum levels of tumor markers used to 
evaluate cardiac, renal and liver function, and detect the interleukin (IL)-18 rs1946518 polymorphism in breast (BC), 
colorectal (CRC) and prostate cancer (PCa) patients. Methods: Blood samples were collected from 65 female BC, 116 
CRC, 79 PCa and 88 myocardial infarction (MI) patients, and 110 healthy individuals to determine the concentration 
of tumor and cardiac markers. Furthermore, the IL-18 rs1946518 polymorphism was assessed using amplification 
refractory mutation system (ARMS)-PCR. Results: The serum levels of the tumor markers cancer antigen 15-3 (CA 15-3), 
carbohydrate antigen 19-9 (CA 19-9), carcinoembryonic antigen (CEA) and total prostate-specific antigen (TPSA) were 
significantly increased in cancer patients compared with healthy controls. Furthermore, the activity of high-sensitivity 
cardiac troponin T (hs-cTnT) and creatine kinase-myocardial band (CK-MB) was enhanced in MI patients, however, 
their activity was unchanged in cancer patients. The activity of alkaline phosphatase (ALP), and the serum concentration 
of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and urea were markedly elevated in CRC and 
PCa patients, respectively, compared with the control group. Although, no significant differences were observed in the 
-607 C/A polymorphism and allele frequency of IL-18 among BC, CRC patients and healthy individuals, the odds ratio 
(OR) was 1.75 for both C and A allele in BC patients. Therefore, the -607 C/A polymorphism could be considered as 
a risk factor for BC. Conclusion: The aforementioned results suggested that tumor markers could be considered as 
excellent biomarkers for the early detection of BC, CRC and PCa, whereas the concentration of liver enzymes could 
serve as an alternative indicator for the diagnosis of CRC and PCa. Additionally, the rs1946518 polymorphism in the 
IL-18 gene could be considered as a risk factor for the occurrence of BC, CRC and PCa.
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countries and the second leading cause in low- and 
middle-income countries. It has been estimated that 
approximately 1 to 4 deaths in the United States are 
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attributed to cancer (Brown et al., 2012). Breast cancer 
(BC) is the most common malignant tumor and foremost 
cause of death in women globally (Youlden et al., 2014). 
Likewise, prostate cancer (PCa) is one of the most 
common tumors in men, while colorectal cancer (CRC) 
is considered the third most commonly diagnosed type of 
cancer worldwide, with approximately 1.23 million new 
cases each year (Ning et al., 2018)).
Nowadays, several biomarkers are available for the 
early detection and progressive stages of different types of 
cancer using blood samples, including total the prostate-
specific antigen (TPSA) for the diagnosis of PCa, the 
carcinoembryonic antigen (CEA) for gastrointestinal, 
breast and lung cancer, the cancer antigen 125 (CA 125) 
for ovarian cancer, the carbohydrate antigen 19-9 (CA 
19-9) for CRC and pancreatic cancer, and the CA 15-3 
for BC (Diamandis, 2014). Since no cure is available for 
many types of cancer, patients eventually progressing to 
metastatic cancer, which affects other organs such as the 
liver, kidney, heart and lungs, with fatal consequences for 
the patients (Arends et al., 2017). Such organ failure may 
cause more deaths than cancer itself (Frères et al., 2018). 
Therefore, biomarkers are widely used to detect cancer 
at an early stage and have been extensively investigated 
in several studies (Cao and Wang, 2012). Furthermore, 
the risk for cardiac diseases has been regarded as an 
important barrier for cancer therapies, as their mortality 
rate is higher compared with that of cancer (Frères et 
al., 2018). For the majority of tumors, the cancer cell 
metastasis from the primary tumor to surrounding tissues 
and to distant vital organs is responsible for the majority of 
cancer-related deaths, accounting for about 90% of cancer 
cases (Akinyemiju et al., 2018). Therefore, the early 
detection of circulating biomarkers could be considered 
as a highly valuable tool for cancer treatment (Marcuello 
et al., 2019).
Interleukin (IL)-18, a member of the IL-1 family, 
activates the immune cells involved in both innate and 
adaptive immune responses, thus increasing the immune 
defense against tumor cells. It has been reported that 
IL-18 exerts a significant role in tumor progression in 
several types of cancer. The IL-18 gene expression and 
serum levels have been shown to be elevated in blood of 
collected from metastatic patients compared with patients 
without metastasis and healthy individuals (Park et al., 
2007). Additionally, it has been suggested that IL-18 
modulates the immune system for attacking cancer 
cells via inhibiting tumor growth and angiogenesis in 
ovarian cancer, attenuating cell proliferation and invasion 
ability in BC, and increasing the cytotoxic effects of the 
chemotherapeutic drugs on colon malignant cells (Jia et al., 
2016). Several studies have demonstrated the association 
between various types of cancer and polymorphisms on 
the IL-18 gene, despite the chronic inflammatory status 
of cancer patients (Hosseini-Baraftabi et al., 2019; Li et 
al., 2019).
A previous study from our lab, has revealed that 
the number of patients with cancer is increasing in the 
Kurdistan region of Iraq (Qader et al., 2020), however, 
gaps still exists between Kurdistan and the rest of the 
world in terms of number and quality of cancer-related 
publications. Therefore, the present study aimed to 
identify and determine the changes in the levels of the 
most effective and appropriate biomarkers used for the 
early diagnosis of different types of cancer and cardiac 
diseases, and to further investigate the possible association 
between a polymorphism at position -607 C/A (rs1946518) 
of the IL-18 gene and BC, CRC and PCa Kurdish patients.
Materials and Methods
Patients
 A total of 458 individuals were enrolled in the current 
study. Among them, 65 were diagnosed with BC, 116 with 
CRC, 79 with PCa and 88 with myocardial infarction 
(MI). Concurrently, 110 healthy volunteers were also 
included in the study. Participants were recruited from 
Erbil city hospitals. The present study was authorized and 
approved by the Human Ethics Committee of the College 
of Science, Salahaddin University, Erbil. All patients and 
healthy volunteers provided written informed consent for 
the publication of their data in the current study.
Blood collection
Blood samples were obtained by phlebotomy under 
aseptic conditions. Venous blood was aspirated with a 
5 ml syringe, collected in both plain and anticoagulant 
tubes, and maintained at room temperature. Subsequently, 
serum was separated from whole blood, placed in 
microcentrifuge tubes, and stored in a freezer at -60°C 
until used. Blood in the anticoagulant tubes was used for 
subsequent molecular diagnostic analyses based on PCR.
Estimation of tumor and cardiac markers
 The concentration of CA 15-3, CEA, CA 19-9, 
TPSA, hs-cTnT, and CK-MB were determined using the 
Cobas e411 analyzer (Roche Diagnostics GmbH) and a 
ready-to-use reagent kit in individual cassettes, according 
to the manufacturer’s instructions. This detection method 
relies on the measurement of immunoreactivity utilizing 
electrochemiluminescence.
Renal and liver function tests
The serum concentration of creatinine and urea, as well 
as the activity of aspartate transaminase (AST), alanine 
aminotransferase (ALT), and alkaline phosphatase (ALP) 
were measured using the Bt35i and BioLIS 50i automated 
clinical analyzers (Tokyo Boeki Medisys Inc.). This 
detection method relies on the use of a spectrophotometer.
Amplification refractory mutation system (ARMS)-PCR
Genomic DNA was extracted from whole blood, 
as previously described (Hashemi et al., 2017). The 
following primer sequences were used for amplifying 
the IL-18 polymorphism: forward outer primer, 
5’-CCTACAATGTTACAACACTTAAAAT-3’ 
and reverse outer primer,
5’-ATAAGCCCTAAATATATGTATCCTTA-3’;
and forward inner primer, 
5’- GATACCATCATTAGAATTTTGTG-3’ and reverse 
inner primer, 5’- GCAGAAAGTGTAAAAATTATCAA-3’. 
The genotyping of the IL-18 -607 C/A polymorphism was 
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was calculated using the receiver operating characteristic 
(ROC) curve. All values were expressed as median and 
range, and P<0.05 was considered to indicate a statistically 
significant difference. All statistical analyses, calculations 
and graphs were performed using GraphPad Prism 6.0 
software (GraphPad Software, Inc.).
Results
Tumor markers between cancer patients and healthy 
controls
The serum levels of CA15-3, CA19-9 and CEA in 
BC and CRC, and TPSA in PCa patients (P<0.001) were 
significantly increased compared with those noted to 
healthy individuals (Table 1).
 
Levels of cardiac markers between healthy controls, and 
cancer and MI patients
The activity of hs-cTnT (ng/ml) and CK-MB was 
notably elevated in MI patients compared with healthy 
controls, and BC, CRC and PCa patients (P<0.001). 
However, there was no statistically significant difference 
in hs-cTnT and CK-MB levels between BC, CRC and PCa 
patients, and healthy volunteers (Table 2).
Liver and renal function tests between healthy controls 
and cancer patients
The activity of AST, ALT and ALP, and the serum 
assessed using the tetra-primer ARMS (T-ARMS) method, 
as previously described (Taheri et al., 2012). Furthermore, 
PCR was performed using a commercially available PCR 
premix (Genet Bio), according to the manufacturer’s 
recommendations. The PCR reaction was performed in 
a total volume of 20 µl containing 10 µl premix solution, 
3 µl DNA template (concentration, ~100 ng/µl), 1 µl from 
each primer (10 µM) and 3 µl nuclease-free water. The 
PCR conditions were as follows: initial denaturation at 
95°C for 5 min followed by 30 cycles, each consisting of 
30 sec at 95°C (denaturation), 20 sec at 54°C (annealing), 
and 30 sec at 72°C (extension), with a final extension at 
72°C for 10 min. The PCR products were analyzed by 
electrophoresis on a 2% agarose gel supplemented with 
0.5 µg/ml ethidium bromide and were then visualized 
under ultraviolet light. Product sizes were 208 bp for 
the C allele, 278 bp for the A allele, and 440 bp for the 
control band.
Statistical analysis
The statistical analysis for the serological data and 
the comparison between the tumor and control groups 
were performed using the Mann-Whitney U test (P<0.05). 
Cardiac function data were compared with those of 
the control and MI groups using the Kruskal-Wallis 
test. Normality tests, namely D’Agostino and Pearson 
omnibus, Shapiro-Wilk and KS normality tests, were 
carried out for all data. The area under the curves (AUC) 
Figure 1. ROC Curve for the Level of Serum Tumour Markers, Liver and Renal Function Tests in BC, CRC and PCa 
Patients. A, B, C represent Ca15-3, CEA, liver and renal function tests in BC patients, respectively. D, E, F represent 
Ca19-9, CEA, liver and renal function tests in CRC patients, respectively. G, H, I represent TPSA, liver and renal 
function tests in PCa patients, respectively.
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concentration of urea and creatinine were unchanged in 
BC patients, whereas ALP was significantly increased 
in CRC patients compared with healthy individuals 
(P<0.001). Furthermore, the activity of AST and ALT, 
and urea serum levels were significantly increased in 
PCa patients compared with the control group (Table 3).
Selection of the biomarkers
 As shown in Figure 1, CEA and CA15-3 were the most 
efficient biomarkers for the early detection of BC, with 
AUC values of 1 and 0.97, respectively. In addition, CA 
19-9, CEA and ALP were the most efficient biomarkers for 
CRC (AUC, 0.87, 0.86 and 0.85, respectively), and TSPA 
and ALP for PCa (AUC, 0.99 and 0.91, respectively). 
Furthermore, urea, creatinine and AST were considered 
as good indicators for detecting PCa, with AUC values 
of 0.75, 0.7 and 0.76, respectively.
Genotypes and allele distribution of the IL-18 
polymorphism
 The distributions of the genotype and allele frequencies 
of the IL18-607 C/A polymorphism in patients and 
healthy groups are shown in Table 4. The results showed 
that 38.88% of BC patients exhibited the homozygous 
CC genotype, 50% the heterozygous CA genotype and 
11.22% the homozygous AA genotype. In addition, 18 and 
82% of CRC patients presented the homozygous CC and 
heterozygous CA genotype, respectively. The genotype 
rates of the -607 C/A polymorphism in healthy individuals 
were 46, 54 and 0.0% for CC, CA and AA genotype, 
respectively. However, no significant differences were 
observed in the distribution of the -607 C/A polymorphism 
of the IL-18 gene among BC and CRC patients, and 
healthy individuals (P>0.05). As shown in Table 4, the C 
allele frequency was 61% in BC and 59% in CRC patients, 
Control BC CRC PCa
Ca15-3 19.47 (13.38-24.07) 52.63 (35.28,130.8)***
CEA 1.57 (0.97-2.13) 15.6 (6.74-52.75)***
Ca19-9 5.77 (1.79-6.41) 19.37(9.18-46.16)***
CEA 1.105 (0.57-1.59) 3.1 (1.88-22)***
TPSA 1.26 (0.62-2.98) 64.01 (18.93-165.7)***
**, represents P value 0.01; ***, represents P value 0.001 
Table 1. Comparison between Serum Levels of Ca15-3 (U/ml) and CEA (ng/mL), Ca19-9 (U/ml) and CEA (ng/ml) 
and TSPA (U/ml) in Control, Breast, Colorectal and Prostate Cancer Patients
Control MI BC CRC PCa
hs-TnT 0.005 (0.004-0.008)*** 0.034 (0.02-0.086) 0.003 (0.003-0.003)*** 0.003 (0.003,0.0055) *** 0.003 (0.003-0.0055)***
CK-MB 16.3 (14, 18.83)** 38.4 (28.7, 80.35) 22.65 (14.73, 26.38)** 15.14 (7.21-43.91)*** 6.82 (5.86, 12.3)***
Table 2. Comparison between Serum Levels of hs-TnT (ng/ml) and CK-MB (IU) in Control, MI, Breast, Colorectal 
and Prostate Cancer Patients
**, represents P value 0.01; ***, represents P value 0.001 
Control BC CRC PCa
AST 21.55 (15.8, 28.83) 21 (17,29. 5) 24 (19, 35) 27.9 (22.53,39.25)*
ALT 17.1 (11.33, 31.75) 15 (9.5, 26) 18 (12, 29.3) 16.25 (11.38, 29.05)
ALP 89.9 (65.4, 112) 84 (35.44, 202.2) 198 (118.4, 269)*** 291 (224,733.4)***
Urea 34.15 (28.8, 39.6) 36.46 (32.5, 41) 34 (26.8, 39) 44 (37, 61)**
Crtn 0.85 (0.6, 1.23) 0.89 (0.76, 1.11) 0.87 (0.75, 1.05) 1.08 (0.81, 1.56)
Polymorphism Control BC CRC PCa
% OR 95% Cl P 
value
% OR 95% Cl P 
value
% OR 95% Cl P 
value
CC 46 38.88 1 - - 18 1 - - 24.1 1 -
CA 54 50 1.13 0.27-4.64 0.87 82 3.98 0.63-24.74 0.131 61.1 0.46 0.2 to 1.08 0.092
AA 0 11.22 5 0.2-122.8 0.18 - - - - 14.8 0.03 0.002 to 0.63 0.001
AA+CA 54 61.22 1.38 0.34-5.51 0.65 - - - - 75.9 0.37 0.16 to 0.86 0.024
C 73 61 1.75 0.61-5.01 0.29 59 1.9 0.59-6.16 0.28 54.6 0.45 0.248 to 0.8 0.006
A 27 39 41 45.4
Table 4. The Genotypes and Allele Distribution of IL-18 Polymorphism in Control, Breast, Colorectal, and Prostate 
Cancer Patients
*, represents P value 0.05; **, represents P value 0.01; ***, represents P value 0.001
Table 3. Comparison between Renal and Liver Function Tests in Control, Breast, Colorectal, and Prostate Cancer 
Patients
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while the A allele frequency was 39 and 41%, respectively. 
In healthy individuals, the C and A allele frequencies were 
73 and 27%, respectively. 
There were no significant differences in the allele 
frequency between patients and healthy controls (P>0.05). 
Additionally, the odds ratio (OR) value was 1.75 for both 
C and A allele in BC patients. Therefore, the -607 C/A 
polymorphism could be considered as a risk factor for 
BC. Furthermore, the frequency rates of homozygous CC, 
heterozygous CA and homozygous AA genotypes in BC 
and PCa patients were 24.1, 61.1 and 14.8%, respectively. 
In addition, the. CC and CA genotype frequency rates were 
46 and 54% in healthy subjects, respectively, whereas the 
AA genotype was not detected. Furthermore, the IL18 
-607 C/A AA genotype was associated with a significantly 
increased risk for PCa compared with the IL18 -607 C/A 
CC genotype [P=0.001, OR=0.033, 95% confidence 
interval (CI)=0.002-0.633)]. Additionally, a significant 
association was identified for the recessive model (CC 
vs. AA/CA: OR=0.372, 95% CI=0.161-0.858, P=0.024). 
However, no significant association was observed in 
the heterozygote model (CA vs CC: OR=0.462, 95% 
CI=0.197-1.081, P=0.092). Finally, the frequency rate of 
the carrier for the mutant A allele was significantly higher 
in PCa patients compared with healthy volunteers, and 
a statistically significant difference was observed in the 
frequency rates between the two IL-18 alleles (C vs A: 
OR=0.445, 95% CI=0.248-0.796, P=0.006).
Discussion
The results of the present study indicated that the 
tumor markers CA 15-3, CA 19-9 and TPSA were the best 
biomarkers for detecting BC, CRC and PCa, respectively. 
In addition, the results revealed that CEA could serve as 
an excellent general tumor biomarker, and especially for 
CRC. Consistent with our findings, a meta-analysis from 
China confirmed the association between the CA 15-3 
serum levels with BC susceptibility (Fu and Li, 2016). 
On the other hand, it has been reported that the serum 
levels of the CA15-3 and CEA biomarkers may be used 
for acquiring sufficient information about the disease 
and its progression status, when tissue specimens are 
not available (Li et al., 2019). Furthermore, a previous 
study has suggested that the increased preoperative serum 
CA 19-9 levels are considered as a prognostic factor for 
CRC (Shin et al., 2019). Additionally, CEA is positively 
correlated with CRC stage and patient’s age, while its 
levels are significantly increased in male patients (Ng 
et al., 2017). A recent study has suggested that initial 
patient evaluation and treatment decisions are based on 
a risk stratification scheme that incorporates the three 
most important prognostic biomarkers at diagnosis: the 
clinical stage, biopsy Gleason grade/score, and serum PSA 
(Gaudreau et al., 2016). 
PSA is the most widely used biomarker for the early 
detection of PCa. Other researchers have suggested that 
CA15-3 alone is not sufficient for the early detection of BC 
and its nodal status and grade, however, they accept that 
it may be considered as a pre-diagnostic marker for more 
aggressive phenotypes (Kazarian et al., 2017). Morita 
et al demonstrated that there was no difference in the 
diagnostic value of CA 19-9 and CEA regarding the early 
detection of CRC. In addition, they hypothesized that CA 
19-9 could not be used to predict the prognosis or relapse 
of CRC. Correspondingly, the authors showed that the 
sensitivity of serum CA19-9 was low, therefore, they did 
not recommend the addition of serum CA19-9 biomarker 
to the current standard surveillance strategies (Okamura et 
al., 2017). PSA has several limitations as a biomarker, as 
it is not able to well distinguish between prostate cancer 
and benign prostatic hyperplasia or between indolent and 
aggressive prostate cancers (Romero Otero et al., 2014).
Furthermore, the results of the present study 
demonstrated that the hs-cTnT and CK-MB biomarkers 
were significantly elevated in MI individuals, but not 
in BC, CRC and PCa patients compared with healthy 
volunteers. Therefore, the high specificity and selectivity 
of methods that are based on the detection of troponins 
led to the inclusion of troponin levels into the criteria for 
the diagnosis of MI (Adamcova et al., 2016). In addition, 
it has been suggested that there is no significant risk of 
cardiac failure in BC patients nor healthy individuals, 
when the levels of CK-MB are reduced (Blaes et al., 2015). 
However, no association has been documented between 
the survival rate and elevated hs-cTnT levels in BC and 
PCa patients (Florido et al., 2019).
Further studies on liver biomarkers have revealed that 
ALP may be considered as a valuable and excellent hepatic 
biomarker for the early detection of BC, CRC and PCa. 
Liver injury and the resulting biochemical abnormalities 
are very common in cancer patients, may be due to 
metastasis, concomitant drugs, or previous liver damage, 
such as cirrhosis (Field et al., 2008). ALP has been found 
to be a valuable tumor marker with high specificity in 
detecting CRC (Saif et al., 2005), PCa (Rao et al., 2017) 
and metastatic and different stages of BC (Singh et al., 
2013). However, a study demonstrated that CA15-3 was 
a better indicator for predicting BC relapse than ALP, 
while the combination of both biomarkers exhibited the 
best prediction results on BC relapse (Keshaviah et al., 
2007). Furthermore, ALP velocity appears to be a strong 
independent predictor of bone metastases and overall 
survival in men with increased PSA levels (Metwalli et 
al., 2014).
The expression of IL-18 has been previously 
investigated in several types of cancer, including gastric 
and colon carcinomas. In colon adenocarcinomas, reduced 
or abolished IL-18 synthesis levels have been detected, 
thus suggesting that IL-18 may play a tumor-suppressive 
role (Cao et al., 1999). Only one previous study has 
investigated the association between the IL-18 -607 
A/C polymorphism and malignancy. In this study, no 
association between this specific polymorphism and oral 
cancer was detected (Jia et al., 2016). Genetic alterations 
such as single nucleotide polymorphisms are considered 
as major risk factors for BC (Zhao et al., 2012). 
The present study aimed to investigate the association 
between an IL-18 polymorphism and BC, CRC and PCa. 
It has been reported that the -607 A/C polymorphism 
affects the transcription of the IL-18 gene in patients with 
CRC and healthy controls. The results of the current study 
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revealed that A/C heterozygotes exhibited an increased 
risk for CRC, while homozygotes for the highly presented 
C allele were protected against this type of cancer. 
This finding was in accordance with a previous study 
demonstrating that IL-18 was downregulated in CRC 
(Pagès et al., 1999). However, no association between the 
IL-18 -607 C/A polymorphism and susceptibility to BC 
was observed in the present study population. This finding 
was not consistent with a previous study demonstrating 
that the IL-18 serum levels were notably increased in 
metastatic compared with non-metastatic BC patients. In 
addition, the authors suggested that IL-18 could contribute 
to doxorubicin resistance (Günel et al., 2002). Therefore, 
due to its dual roles in both drug resistance and tumor 
metastasis, IL-18 may serve as a target for BC therapy. It 
has been shown that IL-18, in synergy with IL-12, plays 
a key role in Th1 responses by upregulating IFN-γ, and 
exhibits anti-tumor activities via mediating the increase 
of NK cell activity and induction of tumor cell apoptosis 
(Srabović et al., 2011). Furthermore, the increased IL-18 
levels serve a major role in PCa cell growth, invasion, 
and metastasis (Nong et al., 2013). Therefore, it has been 
suggested that the elevated secretion of IL-18BP by PCa 
cells indicates the effort of cancer cells to overcome 
immune surveillance (Fujita et al., 2011). In addition, 
IL-18 potentiates antitumor immunity in the tumor 
microenvironment via the innate and adaptive immune 
responses (Tse et al., 2011).
Although, CA 15-3, CA 19-9, CEA, and TPSA are still 
considered as excellent biomarkers for the early detection 
of BC, CRC and PCa, the levels of liver enzymes may 
serve as alternative indicators for the early detection of 
CRC and PCa. The findings of the present study did not 
support a significant association between the IL-18 -670 
C/A polymorphism and the risk of BC, CRC and PCa. 
However, this polymorphism may be regarded as a risk 
factor for BC, CRC and PCa. Therefore, further studies 
with larger number of study participants from different 
ethnic groups should be performed to further investigate 
the diagnostic potential of the aforementioned biomarkers. 
The results of these studies may exhibit a beneficial 
clinical effect.
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